SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it received Ethics Committee approvals from Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel, to conduct the Company’s Phase IIb clinical study for SCI-110 in patients suffering from Tourette Syndrome. The Company is evaluating additional clinical sites to join the Phase 2b trial to expedite patient enrollment in a timely manner.

KWESST Micro Systems Inc. (TSXV: KWE) (OTCQB: KWEMF) (FSE: 62U), a developer of next-generation tactical systems for military, security, and personal defense markets, announced that New York-based Persistent Systems, LLC, an industry leader in mobile ad hoc networking (MANET) solutions, has designated KWESST an Authorized Integrator of its products. It is a solution that's being used extensively by military, public safety, and commercial customers in the United States, Canada, and other countries for secure and scalable mobile networking.

SPI Energy Co., Ltd., (NASDAQ:SPI), a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions for business, residential, government, logistics and utility customers, announced its SPI Solar division has begun development for a 7.2MWac/8.39MWdc community solar project on 34 acres in Southern California. "California is an inherently sustainable market, underpinned by a growing economy and appetite for energy with well-defined clean energy targets,” said Xiaofeng Denton Peng, Chairman and CEO of SPI Energy. Approximately 33% of California's electricity came from renewable energy in 2019 and the state is targeting 50% renewable generation by 2025.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, recently announced the company has completed the manufacturing of GP2, released 3 clinical lots, and started the stability testing program for these lots. Dr. Jaye Thompson, VP Clinical and Regulatory Affairs, commented, “We continue to make progress towards opening up our first sites. We just completed our first Data Safety Management Board (DSMB) meeting and are currently scheduling our initial Steering Committee Meeting with the lead clinicians of FLAMINGO-01. Our electronic data capture and inventory management systems are anticipated to go live in June. We are working to address all FDA issues rapidly so that the study can be initiated shortly.”